Overview
- Revenue rose 23% to $2.51 billion and adjusted EPS reached $2.40, topping estimates of $2.40 billion and $1.98, as shares climbed about 15% after hours to $534.47.
- Worldwide da Vinci procedures grew approximately 20% year over year, the company placed 427 systems versus 379 a year ago, and the installed base reached 10,767 systems, up 13%.
- Management now expects 2025 worldwide da Vinci procedure growth of about 17% to 17.5%, up from 15.5% to 17%, and projects 2025 gross margin of 67% to 67.5% versus 69.1% in 2024.
- The FDA cleared AI-driven software for the Ion bronchoscopy platform that integrates advanced imaging and navigation, including real-time tomosynthesis updates, with a limited U.S. rollout in 2025 and broader launch in 2026.
- BTIG cut its price target to $529 while maintaining a Buy rating and citing policy and macro risks, as long-term investors such as Coatue and Baron Funds highlighted enduring competitive strengths.